Nitrobenzene Compounds Inhibit Expression of VCAM-1

doi:10.1016/S0960-894X(01)00306-7

Bioorganic & Medicinal Chemistry Letters

Volume 11, Issue 14, 23 July 2001, Pages 1823-1827

https://doi.org/10.1016/S0960-894X(01)00306-7 Get rights and content

Abstract

A series of nitrobenzene compounds has been discovered as potent inhibitors of VCAM-1 expression and, therefore, potential drug candidates for autoimmune and allergic inflammatory diseases. Structure–activity relationship (SAR) studies showed that a nitro group and two other electron-withdrawing groups are essential for these compounds to be potent inhibitors of VCAM-1 expression.

A series of nitrobenzene compounds has been discovered as potent inhibitors of VCAM-1 expression.

Section snippets

Acknowledgements

The authors thank Dr. J. Sikorski for critically proofreading the manuscript of this publication.

References (24)

T.A. Springer
Cell
(1994)
C.A. Foster
J. Allergy Clin. Immunol.
(1996)
A.B. Kay
J. Allergy Clin. Immunol.
(1991)
U. Hommel et al.
FEBS Lett.
(1996)
R.R. Cobb et al.
FEBS Lett.
(1996)
S. Kapiotis et al.
Life Sci.
(1996)
J.W. Pierce et al.
J. Biol. Chem.
(1997)
E.D. Harris
N. Engl. J. Med.
(1990)
L. Castano et al.
Annu. Rev. Immunol.
(1990)
S. Zamvil et al.
Annu. Rev. Immunol.
(1990)

R. Ross

N. Engl. J. Med.

(1986)

M.P. Bevilacqua et al.

Annu. Rev. Med.

(1994)

Cited by (7)

Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone
2011, Journal of Biological Chemistry
Citation Excerpt :
It has two electron withdrawing groups (methylsulfonyl and nitro) on the phenyl ring and an ester linkage with the amide group. This MSNB scaffold has only rarely been disclosed in drug discovery (37, 38). In addition, a search of the PubChem BioAssay database showed that MSNB analogs are active against few targets (PubChem AID 1339 for a ras GTPase assay and AIDs 1304, 1359, and 1861 for a neuropeptide Y receptor type 1 assay), despite having been repeatedly screened in the Molecular Libraries Program.
Thyroid hormone receptors (TRs) are members of the nuclear hormone receptor (NR) superfamily and regulate development, growth, and metabolism. Upon binding thyroid hormone, TR undergoes a conformational change that allows the release of corepressors and the recruitment of coactivators, which in turn regulate target gene transcription. Although a number of TR antagonists have been developed, most are analogs of the endogenous hormone that inhibit ligand binding. In a screen for inhibitors that block the association of TRβ with steroid receptor coactivator 2 (SRC2), we identified a novel methylsulfonylnitrobenzoate (MSNB)-containing series that blocks this interaction at micromolar concentrations. Here we have studied a series of MSNB analogs and characterized their structure activity relationships. MSNB members do not displace thyroid hormone T₃ but instead act by direct displacement of SRC2. MSNB series members are selective for the TR over the androgen, vitamin D, and PPARγ NR members, and they antagonize thyroid hormone-activated transcription action in cells. The methylsulfonylnitro group is essential for TRβ antagonism. Side-chain alkylamine substituents showed better inhibitory activity than arylamine substituents. Mass spectrum analysis suggested that MSNB inhibitors bind irreversibly to Cys-298 within the AF-2 cleft of TRβ to disrupt SRC2 association.
Discovery of novel heteroaryl-substituted chalcones as inhibitors of TNF-α-induced VCAM-1 expression
2004, Bioorganic and Medicinal Chemistry Letters
Novel chalcone derivatives have been discovered as potent inhibitors of TNF-α-induced VCAM-1 expression. Thienyl or benzothienyl substitution at the meta-position of ring B helps boost potency while large substitution at the para-position on ring B is detrimental. Various substitutions are tolerated on ring A. A lipophilicity–potency relationship has been observed in several sub-series of compounds.
Lead discovery of α,β-unsaturated sulfones from a combinatorial library as inhibitors of inducible VCAM-1 expression
2003, Bioorganic and Medicinal Chemistry Letters
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis
2002, Bioorganic and Medicinal Chemistry Letters
A series of novel phenolic compounds has been discovered as potent inhibitors of TNF-α-inducible expression of vascular cell adhesion molecule-1 (VCAM-1) with concurrent antioxidant and lipid-modulating properties. Optimization of these multifunctional agents led to the identification of 3a (AGI-1067) as a clinical candidate with demonstrated efficacies in animal models of atherosclerosis and hyperlipidemia.
Clinical overview of leukocyte adhesion and migration: Where are we now?
2002, Seminars in Immunology
This article discusses the potential for clinical translation of the large amount of information on the molecular basis of leukocyte–endothelial cell interactions that has been collected over the last twenty years. Areas of current interest include the identification of adhesion molecule expression in inflammation by diagnostic imaging, understanding variability in inflammatory responsiveness and disease susceptibility through identification of adhesion molecule and chemokine polymorphisms and the application to the treatment of inflammatory diseases of monoclonal antibodies and conventional drugs with specific actions on leukocyte adhesion and migration.
Solution-phase parallel synthesis of a pharmacophore library of HUN-7293 analogues: A general chemical mutagenesis approach to defining structure-function properties of naturally occurring cyclic (depsi)peptides
2002, Journal of the American Chemical Society

View all citing articles on Scopus

View full text

Nitrobenzene Compounds Inhibit Expression of VCAM-1

Abstract

Section snippets

Acknowledgements

Cell

J. Allergy Clin. Immunol.

J. Allergy Clin. Immunol.

FEBS Lett.

FEBS Lett.

Life Sci.

J. Biol. Chem.

N. Engl. J. Med.

Annu. Rev. Immunol.

Annu. Rev. Immunol.

N. Engl. J. Med.

Annu. Rev. Med.